Join
Login
Join
Login
"Where Everyone Has an MBA"
Tel: (612) 246-4616
Home
Financial Analysis
Companies
Industries
Glossary
About
Frequently Asked Questions
User Testimonials
Contact Us
Navigation
Home
Financial Analysis
Companies
Industries
Glossary
About
- Frequently Asked Questions
- User Testimonials
Contact Us
Immix Biopharma, Inc. - SIC # 2834 - PHARMACEUTICAL PREPARATIONS
Ticker
Exchange
SIC #
Website
Latest Ticker
IMMX
Nasdaq
2834
www.immixbio.com
Select one of the four (4) financial statement analysis reports below to view the ratio analysis report for your selected company:
Latest Headlines for Immix Biopharma, Inc.
Several Insiders Invested In Immix Biopharma Flagging Positive News
- Feb 5th, 2025 1:17 pm
Immix Biopharma Accelerates Enrollment in U.S. AL Amyloidosis Trial of NXC-201 CAR-T
- Jan 7th, 2025 2:34 pm
Immix Biopharma Announces Positive U.S. Clinical Data From First Four Patients in NEXICART-2 U.S. Trial of sterically-optimized CAR-T NXC-201 in relapsed/refractory Light Chain (AL) Amyloidosis
- Dec 19th, 2024 2:35 pm
Journal of Clinical Oncology Publishes NXC-201 Positive Clinical Results in relapsed/refractory AL Amyloidosis
- Dec 16th, 2024 2:48 pm
Immix Biopharma Announces 75% Complete Response Rate (n=16); 31.5 months Best Response Duration (ongoing) for CAR-T NXC-201 in Relapsed/Refractory AL Amyloidosis Patients at ASH 2024
- Dec 10th, 2024 2:39 pm
Will Immix Biopharma (NASDAQ:IMMX) Spend Its Cash Wisely?
- Dec 10th, 2024 11:36 am
Immix Biopharma to Host Conference Call for Investors, Analysts and Members of the Media
- Dec 9th, 2024 2:33 pm
Immix Biopharma Presents Positive NXC-201 Clinical Data at 66th American Society of Hematology (ASH) Annual Meeting in 16 Relapsed/Refractory AL Amyloidosis Patients
- Nov 25th, 2024 2:32 pm
Immix Biopharma Advances CAR-T NXC-201 to Expansion Cohort Dose Level in U.S. AL Amyloidosis Trial NEXICART-2
- Oct 2nd, 2024 1:32 pm
Immix Biopharma Announces Dr. Raymond Comenzo, Internationally Recognized AL Amyloidosis Expert, Director of the Myeloma and Amyloid Program at Tufts Medical Center, Joins Scientific Advisory Board
- Sep 19th, 2024 1:31 pm
Immix Biopharma Independent Director Acquires 2.6% More Stock
- Aug 29th, 2024 12:49 pm
Immix Biopharma Expands U.S. Clinical Sites for relapsed/refractory AL Amyloidosis Trial NEXICART-2
- Aug 28th, 2024 1:32 pm
What Makes Immix Biopharma (IMMX) a New Buy Stock
- Aug 19th, 2024 4:00 pm
California Institute for Regenerative Medicine Awards Funding for CAR-T NXC-201 U.S. AL Amyloidosis Clinical Trial (NEXICART-2)
- Jul 26th, 2024 1:31 am
Immix Biopharma Doses 1st Patient in U.S. AL Amyloidosis Trial with CAR-T NXC-201
- Jul 8th, 2024 1:31 pm
Is Immix Biopharma (NASDAQ:IMMX) In A Good Position To Invest In Growth?
- Jul 3rd, 2024 11:32 am
Immix Biopharma to Present at the Stifel 2024 Cell Therapy Forum
- Jun 17th, 2024 1:35 pm
Immix Biopharma Insiders Placed Bullish Bets Worth US$625.7k
- May 23rd, 2024 10:12 am
Immix Biopharma Announces Positive NXC-201 Relapsed/Refractory AL Amyloidosis Clinical Data in ASGCT 2024 Late Breaking Oral Presentation
- May 10th, 2024 1:35 pm
Immix Biopharma Awarded European Union Orphan Drug Designation for NXC-201 in Multiple Myeloma
- Apr 29th, 2024 1:39 pm
Scroll